Other sources of non-concordance in recommendations were in the section of “pharmacotherapy for patients with hypertension and no comorbidity” (n = 4) which included the recomendations of thiazide diuretics (ESC-29 and ESC-30) and beta-blocker (ESC-37) as an option for first-line therapy, as well as the recommendation of thiazide diuretics, ACE inhibitors, ARBs, or calcium channel blockers being preferred over beta-blockers as an option for first-line therapy (ESC-38), in adults with hypertension but with no comorbidity requiring initial pharmacotherapy. The gene discussed is ACE; the disease is Hypertension.